Live Chat

ट्रेड BioNTech BNTX

बेचें
 खरीदें

BioNTech लाइव चार्ट

5m 15m 30m 1h 4h 1d 1w

उपकरण मूल बातें

Weekly Search
Weekly
Daily
दिनांक बंद करें परिवर्तन (%) परिवर्तित करें खुला उच्च कम

नवीनतम समाचार

Frances Wang 2024 Dec 19, 16:00

Analyst revises Amazon stock forecast following major 'moonshot' initiative

Stocks
Frances Wang 2024 Dec 19, 16:00

Stock market today: 3 bullish stocks that J.P. Morgan Just Upgraded

Stocks
Frances Wang 2024 Dec 19, 16:00

Bitcoin news today: Jerome Powell Says Fed Won’t Hold Bitcoin

Cryptocurrencies
Frances Wang 2024 Dec 19, 16:00

Gold performance and prediction: how high could gold price go?

Commodities
UK GDP
Dyogenes Diniz 2024 Dec 19, 16:00

Week ahead: Last full week of 2024 in the Financial Markets

Forex Indices
Frances Wang 2024 Dec 18, 16:00

Stock market today: Nasdaq Hits Record Highs as Tesla Achieves New Peaks

Stocks
Frances Wang 2024 Dec 18, 16:00

Dow Jones tumbles 1,100 points: why did the stock market go down today?

Stocks
Frances Wang 2024 Dec 18, 16:00

Super Micro Shares Drop 8% Following Nasdaq 100 Removal

Stocks

जानकारी

स्प्रेड

0.9179

स्प्रेड (%)

0.8157 %

लीवरेज

1:5

ओवरनाइट ब्याज विक्रय

-0.0597 %

overnight_interest_sell

-0.0292 %

मुद्रा

USD

ट्रेडिंग घंटे

बाज़ार बंद है

सोमवार

14:31 - 20:59

मंगवार

14:31-17:59

गुरुवार

14:31-20:59

शुक्रवार

14:31-20:59

विश्लेषण और सांख्यिकी

खुला

---

पिछला बंद

---

52 सप्ताह उच्च/निम्न्च

--- – ---

बाज़ार आकार

27109799936

बकाया शेयर

239740000

प्राप्ति की तिथि (आगे)

0000-00-00

लाभांश आय 

2022-06-17

पूर्व-लाभांश तिथि

2022-06-02

अग्रिम वार्षिक लाभांश दर 

0

अग्रिम वार्षिक लाभांश आय

0

EPS

-2.04

इस उपकरण के बारे में अधिक जानें

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

संबंधित उपकरण

संपत्ति
बेचें
खरीदें
(%) परिवर्तित करें

अब ट्रेड करें

अब ट्रेड करें

अब ट्रेड करें

अब ट्रेड करें
view_all_instruments
Trustpilot
Live Chat